TY - JOUR
T1 - Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections
AU - Geisbert, Thomas W.
AU - Feldmann, Heinz
N1 - Funding Information:
This work is supported by the intramural and extramural research programs of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant number U01 AI082197 to T. W. G.); and the National Microbiology Laboratory of the Public Health Agency of Canada.
PY - 2011/11/1
Y1 - 2011/11/1
N2 - The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.
AB - The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.
UR - http://www.scopus.com/inward/record.url?scp=80054741833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054741833&partnerID=8YFLogxK
U2 - 10.1093/infdis/jir349
DO - 10.1093/infdis/jir349
M3 - Article
C2 - 21987744
AN - SCOPUS:80054741833
SN - 0022-1899
VL - 204
SP - S1075-S1081
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - SUPPL. 3
ER -